{"id":68772,"date":"2026-02-21T15:51:18","date_gmt":"2026-02-21T15:51:18","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68772"},"modified":"2026-10-15T10:21:51","modified_gmt":"2026-10-15T10:21:51","slug":"retatrutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/retatrutide\/","title":{"rendered":"Retatrutida"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Retatrutida?<\/h3>\n<p style=\"margin: 0;\">Retatrutide (LY3437943) is a peptide and the first <strong>agonista triplo de receptores<\/strong> que atua nos receptores de GLP-1, GIP e glucagon em uma \u00fanica mol\u00e9cula. Nos ensaios de fase 2 (Jastreboff 2023, NEJM), promoveu redu\u00e7\u00e3o m\u00e9dia de peso de <strong>24,2% em 48 semanas<\/strong> \u2014 higher than any other published metabolic peptide to date. Available in 5\u00a0mg to 60\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2381089-83-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4731.4 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agonista triplo modificado de GIP\/GLP-1\/GCGR (39 res\u00edduos, lipidado; propriet\u00e1rio Lilly LY-3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (ou conforme fornecido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de uso mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 Retatrutida<\/h2>\n<p><strong>Retatrutida<\/strong> (designa\u00e7\u00e3o investigacional <strong>LY3437943<\/strong>) is a synthetic 39-amino-acid peptide developed by Eli Lilly as the first clinical-stage triple agonist of the GLP-1, GIP, and glucagon receptors. Where earlier incretin peptides act on one receptor (semaglutide \u2014 GLP-1) or two (tirzepatide \u2014 GLP-1 plus GIP), retatrutide engages all three metabolic receptors simultaneously. This distinct pharmacology is being studied for obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD\/MASH), and hypertension-linked metabolic syndrome. The peptide has a molecular weight of approximately 4,731.4\u00a0Da, empirical formula C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub>, and is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For deeper mechanism, trial, and outlook detail, see our full <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-triple-agonist-weight-loss-guide\/\">Retatrutide guide<\/a>. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonista Triplo de GLP-1\/GIP\/Glucagon<\/h2>\n<p>O perfil de receptores da Retatrutida \u00e9 o que a diferencia de todos os outros pept\u00eddeos metab\u00f3licos atualmente no mercado ou em ensaios cl\u00ednicos avan\u00e7ados. Cada um dos tr\u00eas receptores contribui com uma via distinta para os efeitos observados na composi\u00e7\u00e3o corporal, controle glic\u00eamico e balan\u00e7o energ\u00e9tico:<\/p>\n<ul>\n<li><strong>Receptor de GLP-1<\/strong> \u2014 o mesmo receptor ativado pela semaglutida (Ozempic, Wegovy) e liraglutida. A agoniza\u00e7\u00e3o retarda o esvaziamento g\u00e1strico, aumenta a sinaliza\u00e7\u00e3o de saciedade no hipot\u00e1lamo e estimula a secre\u00e7\u00e3o de insulina dependente de glicose pelas c\u00e9lulas beta pancre\u00e1ticas.<\/li>\n<li><strong>Receptor de GIP<\/strong> \u2014 a segunda via adicionada pela tirzepatida (Mounjaro, Zepbound). A agoniza\u00e7\u00e3o de GIP melhora a sensibilidade \u00e0 insulina no tecido adiposo, reduz o teto de n\u00e1usea do GLP-1 isolado e apoia a efici\u00eancia do manuseio de lip\u00eddios nos adip\u00f3citos.<\/li>\n<li><strong>Receptor de glucagon<\/strong> \u2014 o novo terceiro caminho exclusivo do retatrutida. O agonismo do glucagon aumenta o gasto energ\u00e9tico basal, promove a oxida\u00e7\u00e3o lip\u00eddica hep\u00e1tica e reduz a gordura do f\u00edgado \u2014 efeitos que a dupla GLP-1\/GIP n\u00e3o reproduz.<\/li>\n<\/ul>\n<p>Because increased energy expenditure via glucagon stacks additively on top of the appetite suppression driven by GLP-1\/GIP, retatrutide produces both a larger energy deficit and a more favourable body-composition profile in preclinical models than dual-agonist peptides. In phase 2 data, fat-mass loss accounted for the majority of total weight reduction, with preserved lean mass in the higher dose arms. <\/p>\n<h2>Dados de Estudos Publicados<\/h2>\n<p>O principal conjunto de dados do retatrutida \u00e9 o estudo de obesidade da fase 2 publicado por Jastreboff e colegas no <em>New England Journal of Medicine<\/em> em junho de 2023 (n = 338 participantes com obesidade, per\u00edodo de tratamento de 48 semanas). Na dose mais alta testada de 12 mg semanal, os participantes apresentaram uma redu\u00e7\u00e3o m\u00e9dia de peso corporal de <strong>24,2% em rela\u00e7\u00e3o \u00e0 linha de base<\/strong>. The comparator semaglutide arm in the STEP-1 trial produced 14.9% reduction at 68 weeks and the tirzepatide arm in SURMOUNT-1 produced 22.5% at 72 weeks \u2014 so retatrutide achieved a numerically larger reduction in a shorter treatment window. Head-to-head comparative trials have not yet been published. A parallel phase 2 diabetes programme (Rosenstock et al., <em>Lancet<\/em> 2023) demonstrated HbA1c reductions of up to 2.16 percentage points at 36 weeks in participants with type 2 diabetes, again at the 12\u00a0mg weekly dose. A phase 2 NAFLD sub-study reported a 51.3% relative reduction in liver-fat content after 24 weeks at the 8\u00a0mg dose \u2014 the largest liver-fat reduction reported for any incretin-class peptide to date. Eli Lilly is currently running the TRIUMPH phase 3 programme, including <strong>TRIUMPH-1<\/strong> (obesidade), <strong>TRIUMPH-2<\/strong> (obesidade com diabetes tipo 2), <strong>TRIUMPH-3<\/strong> (obesidade com doen\u00e7a cardiovascular), e <strong>TRIUMPH-4<\/strong> (apneia do sono mais obesidade). Os resultados da fase 3 devem embasar a eventual submiss\u00e3o regulat\u00f3ria. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Retatrutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesidade e regula\u00e7\u00e3o do peso corporal<\/strong> \u2014 trabalhos mecan\u00edsticos sobre sinaliza\u00e7\u00e3o de apetite, cin\u00e9tica de esvaziamento g\u00e1strico e gasto energ\u00e9tico em modelos de roedores e in vitro<\/li>\n<li><strong>Sensibilidade \u00e0 insulina e homeostase da glicose<\/strong> \u2014 efeitos na secre\u00e7\u00e3o de insulina, produ\u00e7\u00e3o hep\u00e1tica de glicose e disposi\u00e7\u00e3o perif\u00e9rica de glicose<\/li>\n<li><strong>Esteatose hep\u00e1tica \/ MASH<\/strong> \u2014 liver fat mobilisation and transaminase response in fatty-liver study models<\/li>\n<li><strong>Farmacologia de receptores<\/strong> \u2014 estudos comparativos de liga\u00e7\u00e3o, seletividade e sinaliza\u00e7\u00e3o downstream atrav\u00e9s da tr\u00edade de receptores GLP-1\/GIP\/glucagon<\/li>\n<li><strong>Comparative metabolic-peptide studies<\/strong> \u2014 compara\u00e7\u00e3o com tirzepatida (agonista dual de GLP-1\/GIP) e outros compostos investigacionais quanto \u00e0 pot\u00eancia, tolerabilidade e resultados de composi\u00e7\u00e3o corporal. Veja nossa <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide-tirzepatide-vs-semaglutide\/\">compara\u00e7\u00e3o entre tirzepatida e semaglutida<\/a> para a linha de base do agonista dual.<\/li>\n<li><strong>Empilhamento de pept\u00eddeos para cura e recupera\u00e7\u00e3o<\/strong> \u2014 protocols that pair metabolic peptides with repair compounds such as <a href=\"https:\/\/medsbase.com\/pt-br\/bpc-157\/\">BPC-157<\/a> em estudos pr\u00e9-cl\u00ednicos.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o retatrutida se encaixa no cen\u00e1rio de pept\u00eddeos para perda de peso, consulte nosso <a href=\"https:\/\/medsbase.com\/pt-br\/peptide-stacks-for-fat-loss\/\">peptide stacks for fat loss guide<\/a> e o panorama geral <a href=\"https:\/\/medsbase.com\/pt-br\/glp-1-weight-loss-injections-guide\/\">Guia de inje\u00e7\u00f5es para perda de peso GLP-1<\/a>. Navegue pelo cat\u00e1logo completo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks retatrutide in the following lyophilized vial sizes. Each variation is supplied in 10-vial, 20-vial, and 30-vial pack formats, shipped under chilled conditions with reconstitution instructions:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudos piloto de dosagem, rampa de titula\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, most commonly ordered<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dose correspondente ao ensaio (fase 2, bra\u00e7o de alta dose)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended protocols, bulk preparation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs (fewer reconstitutions per protocol)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-throughput studies, cost-per-mg optimisation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Large-batch clinical use<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum bulk option, longest-duration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Todas as concentra\u00e7\u00f5es s\u00e3o fornecidas na mesma forma qu\u00edmica (p\u00f3 liofilizado, pureza \u226599% por HPLC). Frascos com maior quantidade em mg oferecem custo menor por mg, mas requerem volumes menores de reconstitui\u00e7\u00e3o para manter concentra\u00e7\u00f5es padr\u00e3o de seringa U-100 \u2014 consulte a tabela de dilui\u00e7\u00e3o abaixo. <\/p>\n<h2>Compara\u00e7\u00e3o \u2014 Retatrutida vs Tirzepatida vs Semaglutida<\/h2>\n<p>O resumo a seguir \u00e9 baseado em dados de ensaios publicados. A Retatrutida ainda est\u00e1 em desenvolvimento na fase 3 e as compara\u00e7\u00f5es abaixo s\u00e3o entre estudos separados, n\u00e3o cabe\u00e7a a cabe\u00e7a. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptores alvo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glucagon (triplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (duplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (\u00fanico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perda de peso m\u00e1xima publicada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">24,2% em 48 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">22,5% em 72 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">14,9% em 68 semanas<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Frequ\u00eancia de dosagem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status regulat\u00f3rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fase 3 (TRIUMPH) \u2014 investigacional<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprovado pela FDA (Mounjaro\/Zepbound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprovado pela FDA (Ozempic\/Wegovy)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Redu\u00e7\u00e3o de gordura no f\u00edgado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">51,3% em 24 semanas (fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~47% em 52 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~31% em 72 semanas<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Redu\u00e7\u00e3o de HbA1c (T2DM)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -2,16% em 36 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -2,3% em 40 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -1,8% em 40 semanas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Para uma compara\u00e7\u00e3o mais detalhada entre tirzepatide e semaglutide especificamente, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide-tirzepatide-vs-semaglutide\/\">Tirzepatide vs Semaglutide: Perda de Peso, Dosagem e Custo<\/a>. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original de alum\u00ednio. Nessas condi\u00e7\u00f5es, o retatrutide liofilizado permanece est\u00e1vel por at\u00e9 36 meses. Evite ciclos repetidos de temperatura. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> adicione \u00e1gua bacteriost\u00e1tica ao frasco do pept\u00eddeo conforme a tabela de dilui\u00e7\u00e3o acima. Injete a \u00e1gua pela parede lateral do frasco, em vez de diretamente sobre o p\u00f3 liofilizado. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> sacuda \u2014 e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o totalmente reconstitu\u00edda deve estar clara e incolor. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> armazene a solu\u00e7\u00e3o refrigerada a 2\u20138 \u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento e descongelamento degradam a integridade do pept\u00eddeo. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is retatrutide used for in studies?<\/h3>\n<p>Retatrutide is used in studies investigating obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD\/MASH), insulin sensitivity, appetite regulation, and comparative metabolic-peptide pharmacology. It is <strong>n\u00e3o<\/strong> approved by the FDA, EMA, or other regulators for human therapeutic use and is sold here strictly for clinical studies use only. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre retatrutida, tirzepatida e semaglutida?<\/h3>\n<p>O Retatrutide \u00e9 o primeiro agonista triplo de receptores, ligando-se ao GLP-1, GIP, <em>e<\/em> receptores de glucagon em uma \u00fanica mol\u00e9cula. O Tirzepatide se liga ao GLP-1 e ao GIP (duplo). O Semaglutide se liga apenas ao GLP-1 (simples). A via adicional do glucagon no retatrutide aumenta o gasto energ\u00e9tico e reduz a gordura hep\u00e1tica de maneiras que os agonistas duplos e simples n\u00e3o reproduzem. <\/p>\n<h3>Quanta perda de peso o retatrutide demonstrou nos ensaios cl\u00ednicos?<\/h3>\n<p>O estudo de fase 2 sobre obesidade publicado por Jastreboff et al. no NEJM (2023) relatou uma redu\u00e7\u00e3o m\u00e9dia de peso corporal de 24,2% em 48 semanas na dose mais alta testada de 12 mg semanal. Para contexto, o bra\u00e7o de dose mais alta da fase 3 do tirzepatida produziu 22,5% em 72 semanas e o do semaglutida produziu 14,9% em 68 semanas. Os resultados da fase 3 do retatrutida do programa TRIUMPH est\u00e3o pendentes. <\/p>\n<h3>N\u00e3o. A retatrutida est\u00e1 atualmente em desenvolvimento cl\u00ednico de fase 3 no programa TRIUMPH da Eli Lilly e n\u00e3o recebeu aprova\u00e7\u00e3o regulat\u00f3ria da FDA, EMA, MHRA ou qualquer outra autoridade. O pept\u00eddeo vendido por fornecedores apenas para pesquisa \u00e9 para investiga\u00e7\u00e3o laboratorial, n\u00e3o para uso terap\u00eautico humano.<\/h3>\n<p>No. Retatrutide is currently in phase 3 clinical development under Eli Lilly&#8217;s TRIUMPH programme and has not received regulatory approval from the FDA, EMA, MHRA, or any other authority. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries retatrutide in 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, and 60\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis on request. <\/p>\n<h3>Como devo reconstituir o retatrutide?<\/h3>\n<p>Siga o gr\u00e1fico de dilui\u00e7\u00e3o acima. Um frasco de 10 mg com 2,0 mL de \u00e1gua bacteriost\u00e1tica rende 5,0 mg\/mL, ent\u00e3o 40 marcas em uma seringa de insulina U-100 (1 mL \/ 100 unidades) equivalem a 2 mg. Injete a \u00e1gua BAC pela parede lateral, agite suavemente (n\u00e3o sacuda) e aguarde 5 a 10 minutos para dissolu\u00e7\u00e3o antes do uso. <\/p>\n<h3>Como o retatrutide deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerar a 2\u20138 \u00b0C na embalagem original, est\u00e1veis por at\u00e9 36 meses. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerar a 2\u20138 \u00b0C, usar em at\u00e9 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam o pept\u00eddeo. <\/p>\n<h3>What is the typical dose of retatrutide in studies?<\/h3>\n<p>Phase 2 obesity-trial arms tested 1\u00a0mg, 4\u00a0mg, 8\u00a0mg, and 12\u00a0mg weekly doses over 48 weeks. Weight-loss response was dose-dependent, with 24.2% reduction observed at the 12\u00a0mg arm. Clinical protocols typically mirror these trial doses when the intent is to model published efficacy data. <\/p>\n<h3>O retatrutida causa os mesmos efeitos colaterais que outros pept\u00eddeos GLP-1?<\/h3>\n<p>Nos ensaios publicados, os eventos mais comuns relacionados ao tratamento foram efeitos gastrointestinais dependentes da dose \u2014 n\u00e1usea, diarreia, constipa\u00e7\u00e3o \u2014 com perfil semelhante ao do semaglutida e do tirzepatida. A atividade adicional no receptor de glucagon n\u00e3o produziu sinais de seguran\u00e7a inesperados na fase 2, mas o perfil completo de tolerabilidade aguarda os resultados da fase 3. <\/p>\n<h3>Quanto tempo at\u00e9 o retatrutida ser aprovado pela FDA?<\/h3>\n<p>O programa TRIUMPH de fase 3 da Eli Lilly come\u00e7ou a recrutar pacientes em 2023\u20132024, com datas de conclus\u00e3o prim\u00e1ria projetadas para 2025\u20132027, dependendo do sub-ensaio. Supondo resultados positivos, uma submiss\u00e3o \u00e0 FDA poderia ocorrer 12\u201318 meses ap\u00f3s a conclus\u00e3o prim\u00e1ria. Os prazos de aprova\u00e7\u00e3o regulat\u00f3ria s\u00e3o especulativos at\u00e9 que a Lilly anuncie o pedido. <\/p>\n<h3>Qual \u00e9 a meia-vida do retatrutida?<\/h3>\n<p>O retatrutida (LY3437943) tem uma longa meia-vida de elimina\u00e7\u00e3o de aproximadamente 6 dias em dados cl\u00ednicos de Fase I, atribu\u00edda \u00e0 modifica\u00e7\u00e3o com \u00e1cido graxo C18 que permite a liga\u00e7\u00e3o \u00e0 albumina. Essa meia-vida prolongada permite dosagens semanais \u00fanicas, como as usadas nos ensaios cl\u00ednicos. <\/p>\n<h3>Como o retatrutida se compara ao tirzepatida e ao semaglutida?<\/h3>\n<p>O retatrutida \u00e9 um triplo agonista (receptores de GLP-1 \/ GIP \/ glucagon), comparado ao duplo agonismo do tirzepatida (GLP-1 \/ GIP) e ao agonismo \u00fanico do semaglutida (GLP-1). Dados de ensaios cl\u00ednicos de Fase II para o retatrutida relataram redu\u00e7\u00e3o de peso de at\u00e9 24% em 48 semanas \u2014 superando os resultados tanto do tirzepatida quanto do semaglutida em per\u00edodos compar\u00e1veis. Acredita-se que a atividade adicional no receptor de glucagon promova maior gasto energ\u00e9tico e oxida\u00e7\u00e3o de gordura. <\/p>\n<h3>Posso encomendar retatrutida para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia retatrutida para todo o mundo a partir de nossa rede dedicada de envio de pept\u00eddeos. Pedidos contendo apenas pept\u00eddeos se qualificam para nosso servi\u00e7o de envio exclusivo para pept\u00eddeos. Os pedidos s\u00e3o enviados em embalagens com controle de temperatura e rastreamento completo. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Recovery and Performance<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tendon, ligament, gut recovery<\/li>\n<li><a href=\"\/pt-br\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragment \u2014 soft tissue and vascular recovery<\/li>\n<li><a href=\"\/pt-br\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Agonista seletivo de grelina \u2014 pulso de GH limpo sem cortisol\/prolactina<\/li>\n<li><a href=\"\/pt-br\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 An\u00e1logo de GHRH com meia-vida prolongada<\/li>\n<li><a href=\"\/pt-br\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper peptide \u2014 skin and connective tissue regeneration<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Learn the science behind this peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Leia nosso guia completo baseado em evid\u00eancias: <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-triple-agonist-weight-loss-guide\/\"><strong>Retatrutide \u2014 mecanismo, dados de ensaios cl\u00ednicos e perspectivas<\/strong><\/a>. Covers mechanism of action, published study data, typical dosing ranges, reconstitution protocols, stacking considerations, and safety\/contraindication notes.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Auxilia na perda de peso saud\u00e1vel e melhora a fun\u00e7\u00e3o metab\u00f3lica<br data-start=\"62\" data-end=\"65\" \/>\u2705 Ajuda a regular o balan\u00e7o energ\u00e9tico para melhor desempenho di\u00e1rio<br data-start=\"125\" data-end=\"128\" \/>\u2705 Promove maior queima de gordura e efici\u00eancia metab\u00f3lica<br data-start=\"184\" data-end=\"187\" \/>\u2705 Auxilia no controle do apetite e reduz os desejos por comida<br data-start=\"239\" data-end=\"242\" \/>\u2705 Favorece melhores resultados no gerenciamento geral do peso<\/p>\n<p><strong>Retatrutida<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70975,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5445,5444,5447,5446],"class_list":["post-68772","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ly3437943","product_tag-retatrutide","product_tag-triple-agonist","product_tag-triple-g","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/68772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=68772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70975"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=68772"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=68772"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=68772"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=68772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}